Product Quality ‘Wild Card’? Sarepta’s Gene Therapy Manufacturing Process Change Means More Empty Capsids

 
• By Sue Sutter
  
Joker playing card 2
Product quality differences resulting from a manufacturing change for SRP-9001 represents an efficacy and safety wild card, one panelist said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers